S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
NASDAQ:AGLE

Aeglea BioTherapeutics (AGLE) Stock Forecast, Price & News

$11.86
+0.19 (+1.63%)
(As of 09/22/2023 ET)
Compare
Today's Range
$11.57
$12.72
50-Day Range
$10.86
$16.92
52-Week Range
$2.66
$39.00
Volume
52,216 shs
Average Volume
107,846 shs
Market Capitalization
$48.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.38

Aeglea BioTherapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
103.1% Upside
$24.38 Price Target
Short Interest
Healthy
1.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.22mentions of Aeglea BioTherapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.95) to ($1.56) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

486th out of 968 stocks

Pharmaceutical Preparations Industry

210th out of 445 stocks


AGLE stock logo

About Aeglea BioTherapeutics (NASDAQ:AGLE) Stock

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

AGLE Price History

AGLE Stock News Headlines

This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
Aeglea Biotherapeutics (AGLE) Gets a Buy from Stifel Nicolaus
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
Aeglea BioTherapeutics Announces Reverse Stock Split
Aeglea BioTherapeutics Appoints Scott Burrows As Chief Financial Officer
Aeglea BioTherapeutics (NASDAQ: AGLE)
Funding wrap: Former Dell Med dean raises $30M
See More Headlines
Receive AGLE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aeglea BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

AGLE Company Calendar

Last Earnings
8/11/2023
Today
9/22/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AGLE
Employees
14
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$24.38
High Stock Price Forecast
$37.50
Low Stock Price Forecast
$12.50
Forecasted Upside/Downside
+98.7%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
6 Analysts

Profitability

Net Income
$-83,820,000.00
Net Margins
-22,195.36%
Pretax Margin
-22,209.53%

Debt

Sales & Book Value

Annual Sales
$2.33 million
Book Value
$20.45 per share

Miscellaneous

Free Float
3,918,000
Market Cap
$49.69 million
Optionable
Optionable
Beta
2.53

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Jonathan D. Alspaugh M.B.A. (Age 40)
    Pres, CFO & Principal Accounting Officer
    Comp: $568.55k
  • Mr. James Paul Kastenmayer J.D. (Age 51)
    Ph.D., Consultant
    Comp: $611.84k
  • Dr. Cameron Turtle DPHIL (Age 33)
    Ph.D., Chief Operating Officer
  • Joey Perrone
    VP of Fin. & Investor Relations
  • Dr. Kelly Boothe Ph.D.
    Sr. Director of Corp. Communications & Investor Relations
  • Ms. Cortney Caudill M.B.A.
    Chief Product Officer













AGLE Stock - Frequently Asked Questions

Should I buy or sell Aeglea BioTherapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aeglea BioTherapeutics in the last twelve months. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AGLE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AGLE, but not buy additional shares or sell existing shares.
View AGLE analyst ratings
or view top-rated stocks.

What is Aeglea BioTherapeutics' stock price forecast for 2023?

6 Wall Street analysts have issued 1 year price targets for Aeglea BioTherapeutics' stock. Their AGLE share price forecasts range from $12.50 to $37.50. On average, they anticipate the company's share price to reach $24.38 in the next twelve months. This suggests a possible upside of 98.7% from the stock's current price.
View analysts price targets for AGLE
or view top-rated stocks among Wall Street analysts.

How have AGLE shares performed in 2023?

Aeglea BioTherapeutics' stock was trading at $11.2475 on January 1st, 2023. Since then, AGLE shares have increased by 9.1% and is now trading at $12.27.
View the best growth stocks for 2023 here
.

Are investors shorting Aeglea BioTherapeutics?

Aeglea BioTherapeutics saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 61,600 shares, a decrease of 96.1% from the August 15th total of 1,570,000 shares. Based on an average daily volume of 256,400 shares, the short-interest ratio is presently 0.2 days. Currently, 1.5% of the company's shares are sold short.
View Aeglea BioTherapeutics' Short Interest
.

When is Aeglea BioTherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our AGLE earnings forecast
.

How were Aeglea BioTherapeutics' earnings last quarter?

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) announced its quarterly earnings results on Friday, August, 11th. The biotechnology company reported ($41.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($4.50) by $37.00. The biotechnology company had revenue of $0.69 million for the quarter. Aeglea BioTherapeutics had a negative trailing twelve-month return on equity of 132.05% and a negative net margin of 22,195.36%.

When did Aeglea BioTherapeutics' stock split?

Aeglea BioTherapeutics's stock reverse split before market open on Friday, September 8th 2023. The 1-25 reverse split was announced on Thursday, September 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What is Anthony Quinn's approval rating as Aeglea BioTherapeutics' CEO?

3 employees have rated Aeglea BioTherapeutics Chief Executive Officer Anthony Quinn on Glassdoor.com. Anthony Quinn has an approval rating of 100% among the company's employees. This puts Anthony Quinn in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Aeglea BioTherapeutics own?
When did Aeglea BioTherapeutics IPO?

(AGLE) raised $60 million in an initial public offering on Thursday, April 7th 2016. The company issued 3,500,000 shares at $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Needham & Company was co-manager.

What is Aeglea BioTherapeutics' stock symbol?

Aeglea BioTherapeutics trades on the NASDAQ under the ticker symbol "AGLE."

Who are Aeglea BioTherapeutics' major shareholders?

Aeglea BioTherapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include VR Adviser LLC (9.70%), Affinity Asset Advisors LLC (7.49%), Driehaus Capital Management LLC (7.10%), Commodore Capital LP (4.45%), Goldman Sachs Group Inc. (0.85%) and BlackRock Inc. (0.81%). Insiders that own company stock include Anthony G Quinn, Armen Shanafelt, Jonathan Alspaugh, Jr Michael Conick Hanley and Marcio Souza.
View institutional ownership trends
.

How do I buy shares of Aeglea BioTherapeutics?

Shares of AGLE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aeglea BioTherapeutics' stock price today?

One share of AGLE stock can currently be purchased for approximately $12.27.

How much money does Aeglea BioTherapeutics make?

Aeglea BioTherapeutics (NASDAQ:AGLE) has a market capitalization of $49.69 million and generates $2.33 million in revenue each year. The biotechnology company earns $-83,820,000.00 in net income (profit) each year or ($71.00) on an earnings per share basis.

How can I contact Aeglea BioTherapeutics?

Aeglea BioTherapeutics' mailing address is 805 LAS CIMAS PARKWAY SUITE 100, AUSTIN TX, 78746. The official website for the company is www.aegleabio.com. The biotechnology company can be reached via phone at (512) 942-2935, via email at investors@aegleabio.com, or via fax at 512-872-5121.

This page (NASDAQ:AGLE) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -